[1]
|
Mozobil, R. (2009) Summary of Product Characteristics. Genzyme Europe B.V., Naarden.
|
[2]
|
Shea, T.C. and DiPersio, J.F. (2009) Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Cellular Therapy. In: Applebaum, F.R., Forman, S.J., Negrin, R.S. and Blume, K.G., Eds., Thomas’ Hematopoietic Cell Transplantation, Wiley-Blackwell, Hoboken, 590-604. https://doi.org/10.1002/9781444303537.ch41
|
[3]
|
Bensinger, W., Appelbaum, F., Rowley, S., et al. (1995) Factors That Influence Collection and Engraftment of Autologous Peripheral-Blood Stem Cells. Journal of Clinical Oncology, 13, 2547-2555.
|
[4]
|
Martin, C., Bridger, G.J. and Rankin, S.M. (2006) Structural Analogues of AMD3100 Mobilise Haematopoietic Progenitor Cells from Bone Marrow in Vivo According to Their Ability to Inhibit CXCL12 Binding to CXCR4 in Vitro. British Journal of Haematology, 134, 326-329. https://doi.org/10.1111/j.1365-2141.2006.06181.x
|
[5]
|
Hatse, S., Princen, K., Bridger, G., De Clercq, E. and Schols, D. (2002) Chemokine Receptor Inhibition by AMD3100 Is Strictly Confined to CXCR4. FEBS Letters, 527, 255-262. https://doi.org/10.1016/S0014-5793(02)03143-5
|
[6]
|
Fricker, S.P., Anastassov, V., Cox, J., et al. (2006) Characterization of the Molecular Pharmacology of AMD3100: A Specific Antagonist of the G-Protein Coupled Chemokine Receptor, CXCR4. Biochemical Pharmacology, 72, 588-596. https://doi.org/10.1016/j.bcp.2006.05.010
|
[7]
|
Gerlach, L.O., Skerlj, R.T., Bridger, G.J. and Schwartz, T.W. (2001) Molecular Interactions of Cyclam and Bicyclam Non-Peptide Antagonists with the CXCR4 Chemokine Receptor. The Journal of Biological Chemistry, 276, 14153-14160. https://doi.org/10.1074/jbc.M010429200
|
[8]
|
Devine, S.M., Flomenberg, N., Vesole, D.H., et al. (2004) Rapid Mobilization of CD34+ Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients with Multiple Myeloma and Non-Hodgkin’s Lymphoma. Journal of Clinical Oncology, 22, 1095-1102. https://doi.org/10.1200/JCO.2004.07.131
|
[9]
|
Flomenberg, N., Devine, S.M., Dipersio, J.F., et al. (2005) The Use of AMD3100 plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization Is Superior to G-CSF Alone. Blood, 106, 1867-1874. https://doi.org/10.1182/blood-2005-02-0468
|
[10]
|
Kouroukis, C., Varela, N., Bredeson, C., Kuruvilla, J. and Xenocostas, A. (2016) Plerixafor for Autologous Stem-Cell Mobilization and Transplantation for Patients in Ontario. Current Oncology, 23, 409. https://doi.org/10.3747/co.23.3137
|
[11]
|
Hosing, C., Saliba, R.M., Ahlawat, S., Korbling, M., Kebriaei, P., Alousi, A., De Lima, M., Okoroji, J.G., McMannis, J., Qazilbash, M. and Anderlini, P. (2009) Poor Hematopoietic Stem Cell Mobilizers: A Single Institution Study of Incidence and Risk Factors in Patients with Recurrent or Relapsed Lymphoma. American Journal of Hematology, 84, 335-337. https://doi.org/10.1002/ajh.21400
|
[12]
|
Olivieri, A., Marchetti, M., Lemoli, R., Tarella, C., Iacone, A., Lanza, F., Rambaldi, A. and Bosi, A. (2012) Proposed Definition of “Poor Mobilizer” in Lymphoma and Multiple Myeloma: An Analytic Hierarchy Process by Ad Hoc Working Group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplantation, 47, 342-351. https://doi.org/10.1038/bmt.2011.82
|
[13]
|
Varmavuo, V., Rimpilainen, J., Kuitunen, H., Nihtinen, A., Vasala, K., Mikkola, M., Kutila, A., Lehtonen, P., Kuittinen, T., Mantymaa, P. and Nousiainen, T. (2014) Engraftment and Outcome after Autologous Stem Cell Transplantation in Plerixafor-Mobilized Non-Hodgkin’s Lymphoma Patients. Transfusion, 54, 1243-1250. https://doi.org/10.1111/trf.12434
|
[14]
|
Mohty, M., Azar, N., Chabannon, C., Le Gouill, S., Karlin, L., Farina, L., Milkovich, G., Ostermann, H., Glaβ, B., Noppeney, R. and Kron, F. (2018) Plerixafor in Poor Mobilizers with Non-Hodgkin’s Lymphoma: A Multi-Center Time-Motion Analysis. Bone Marrow Transplantation, 53, 246-254. https://doi.org/10.1038/s41409-017-0033-0
|
[15]
|
DiPersio, J., Stadtmauer, E., Nademanee, A., et al. (2009) Plerixafor and G-CSF versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. Blood, 113, 5720-5726. https://doi.org/10.1182/blood-2008-08-174946
|
[16]
|
Basak, G.W., Urbanowska, E., Witkowska, M., Zdunczyk, D., Waszczuk-Gajda, A., Skwierawska, K., Drozd-Sokolowska, J., Skibinska, M., Glazer, M., Madry, K. and Torosian, T. (2010) CXCR4 Inhibitor Plerixafor and G-CSF Allow for an Effective Peripheral Blood Stem Cell Collection in Patients Who Failed Previous Mobilization Attempt. Translational Biomedicine, 1, 2.
|
[17]
|
Malik, S., Yanovich, S., Rapoport, A., Badros, A., Hardy, N. and Kocoglu, M. (2015) Outcome Comparison of Lymphoma and Myeloma Patients after Autologous Stem Cell Transplantation (ASCT) with Peripheral Blood Stem Cell Mobilization between Plerixafor (P) Mobilized in Poor Mobilizer Patients and Non-Plerixafor Mobilized Patients. Blood, 126, 5507. https://doi.org/10.1182/blood.V126.23.5507.5507
|